Ovid Therapeutics Inc.

Equities

OVID

US6904691010

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-09 pm EDT			5-day change	1st Jan Change
0.8299 ^USD	-0.71%		+7.31%	-74.23%

Jul. 09	Immunic Names President/COO, Chief Development Officer	MT
Jul. 09	Immunic Names Jason Tardio as COO, Werner Gladdines as Chief Development Officer	MT

Ovid Therapeutics Inc. Appoints Joy A. Cavagnaro and Dr. Bruce A. Sullenger to Scientific Advisory Board

May 26, 2021 at 08:00 am EDT

Ovid Therapeutics Inc. announced the appointment of Joy A. Cavagnaro, Ph.D., and Bruce A. Sullenger, Ph.D. to its Scientific Advisory Board. Joy A. Cavagnaro, Ph.D., DABT, ATS, RAC, FRAPS, has more than 30 years of experience in the biotechnology industry and is the President of Access BIO.

Latest news about Ovid Therapeutics Inc.

Immunic Names President/COO, Chief Development Officer	Jul. 09	MT
Immunic Names Jason Tardio as COO, Werner Gladdines as Chief Development Officer	Jul. 09	MT
Ovid Therapeutics Inc. and Graviton Bioscience Corporation Announce Topline Data from A Phase 1 Clinical Trial Studying OV888/GV101 Capsule	Jul. 01	CI
Ovid Therapeutics Inc.(NasdaqGS:OVID) dropped from Russell 3000E Value Index	Jun. 30	CI
Ovid Therapeutics Inc.(NasdaqGS:OVID) dropped from Russell 2000 Value Index	Jun. 30	CI
Ovid Therapeutics Inc.(NasdaqGS:OVID) added to Russell 3000 Growth Index	Jun. 30	CI
Ovid Therapeutics Inc.(NasdaqGS:OVID) dropped from Russell 3000 Value Index	Jun. 30	CI
Ovid Therapeutics Inc.(NasdaqGS:OVID) dropped from Russell 2500 Value Index	Jun. 30	CI
Ovid Therapeutics Inc.(NasdaqGS:OVID) added to Russell Microcap Growth Index	Jun. 30	CI
Ovid Therapeutics Inc.(NasdaqGS:OVID) added to Russell 3000E Growth Index	Jun. 30	CI
Ovid Therapeutics Inc.(NasdaqGS:OVID) added to Russell 2000 Growth Index	Jun. 30	CI
Ovid Therapeutics Inc.(NasdaqGS:OVID) dropped from Russell Microcap Value Index	Jun. 30	CI
Ovid Therapeutics Inc.(NasdaqGS:OVID) added to Russell 2500 Growth Index	Jun. 30	CI
Ovid Therapeutics Inc.(NasdaqGS:OVID) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Ovid Therapeutics Inc.(NasdaqGS:OVID) dropped from Russell Small Cap Comp Value Index	Jun. 30	CI
Ovid Therapeutics Inc. Announces Reduction of Workforce	Jun. 28	CI
Ovid Therapeutics Inc. Announces Executive Resignations	Jun. 28	CI
Oppenheimer Downgrades Ovid Therapeutics to Market Perform	Jun. 18	MT
B. Riley Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating	Jun. 18	MT
BTIG Adjusts Price Target on Ovid Therapeutics to $5 From $11, Maintains Buy Rating	Jun. 18	MT
HC Wainwright Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating	Jun. 18	MT
Citigroup Adjusts Price Target on Ovid Therapeutics to $1.20 From $3.50, Maintains Neutral Rating	Jun. 18	MT
Top Midday Decliners	Jun. 17	MT
Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback	Jun. 17	DJ
Sector Update: Health Care Stocks Decline Premarket Monday	Jun. 17	MT

Chart Ovid Therapeutics Inc.

Duration

Period

More charts

Company Profile

Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ovid Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8299 USD

Average target price

3.314 USD

Spread / Average Target

+299.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
OVID THERAPEUTICS INC.	-74.23%	59.3M
VERTEX PHARMACEUTICALS INCORPORATED	+19.44%	124B
REGENERON PHARMACEUTICALS, INC.	+20.01%	114B
ARGENX SE	+21.11%	25.83B
BIONTECH SE	-23.72%	19.42B
GENMAB A/S	-18.17%	16.2B
BEIGENE, LTD.	-19.87%	15.31B
SAREPTA THERAPEUTICS, INC.	+55.81%	14.32B
NEUROCRINE BIOSCIENCES, INC.	+8.76%	14.31B
WUXI APPTEC CO., LTD.	-48.79%	14.19B

Bio Therapeutic Drugs